In a nutshell
This study investigated corifollitropin alfa (CFTA; Elonva) in controlled ovarian stimulation (COS). They found that CFTA was effective in normal and poor responder patients.
Some background
The first step in assisted reproduction is oocyte (egg) harvest. Women undergo a procedure called controlled ovarian stimulation (COS). This causes the ovaries to release oocytes. COS can be difficult in some patients. Standard therapy involves a combination of drugs to stimulate ovulation. One of the drugs used is follicle-stimulating hormone (FSH). This hormone is present in the body already. It regulates ovulation.
One of the issues with FSH is that it requires daily injection by the patient. This can cause anxiety for patients. Corifollitropin alfa (CFTA) is a new drug for COS. It is a synthetic form of FSH. It is active much longer than FSH. It does not have to be administered as often. Therefore, it may be preferred by patients. It is unclear if CFTA is effective for COS in all patients.
Methods & findings
This study reviewed 8 clinical trials. These included 4,340 women undergoing fertility treatment. Women were undergoing COS with CFTA or standard therapy (control). The authors analyzed fertility outcomes between the studies. These included ongoing pregnancy rate and live birth rate. The effect on poor responders was also investigated.
There was no difference in ongoing pregnancy rate or live birth rate between groups. There was no difference in other fertility outcomes. This included clinical pregnancy and miscarriage rate. The number and quality of oocytes retrieved after COS with CFTA were significantly higher. The response to CFTA was similar in poor and normal COS responders.
Ovarian hyperstimulation syndrome (a dangerous complication of COS involving painful and swollen ovaries) rates were similar in CFTA and control patients.
The bottom line
The authors concluded that CFTA was effective in normal and poor responder patients for ovarian stimulation.
The fine print
The protocols for COS varied across the trials. The patient characteristics also varied.
What’s next?
If you have any concerns regarding fertility treatment please consult with your physician.
Published By :
Fertility and Sterility
Date :
Apr 01, 2019
